Impact of death receptor signaling on the malignancy of pancreatic ductal adenocarcinoma

European Journal of Cell Biology

Volumn 90, Issue 6-7, 2011, Pages 450-455

  Röder, Christian ^a   Trauzold, Anna ^a   Kalthoff, Holger ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Apoptosis; Cancer of the pancreas; CD95L; Death receptor; PDAC; Signal transduction; TNF; TRAIL

Indexed keywords

DEATH RECEPTOR; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DEXAMETHASONE; EPICATECHIN GALLATE; ETANERCEPT; FAS ANTIGEN; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; LEXATUMUMAB; MAPATUMUMAB; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR RECEPTOR 1;

APOPTOSIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; HUMAN; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION;

ADENOCARCINOMA; ANIMALS; ANTIGENS, CD95; APOPTOSIS; CARCINOMA, PANCREATIC DUCTAL; HUMANS; PANCREATIC NEOPLASMS; RECEPTORS, DEATH DOMAIN; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 79955481608     PISSN: 01719335     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcb.2010.10.008     Document Type: Short Survey

References (77)

1. Aggarwal B.B., Singh S., LaPushin R., Totpal K. Fas antigen signals proliferation of normal human diploid fibroblast and its mechanism is different from tumor necrosis factor receptor. FEBS Lett 1995, 364:5-8.
2. Alderson M.R., Armitage R.J., Maraskovsky E., Tough T.W., Roux E., Schooley K., Ramsdell F., Lynch D.H. Fas transduces activation signals in normal human T lymphocytes. J Exp Med 1993, 178:2231-2235.
3. Ammerpohl O., Trauzold A., Schniewind B., Griep U., Pilarsky C., Grützmann R., Saeger H.D., Janssen O., Sipos B., Klöppel G., Kalthoff H. Complementary effects of HDAC inhibitor 4-PB on gap junction communication and cellular export mechanisms support restoration of chemosensitivity of PDAC cells. Br J Cancer 2007, 96:73-81.
4. Arlt A., Vorndamm J., Müerköster S., Yu H., Schmidt W.E., Fölsch U.R., Schäfer H. Autocrine production of interleukin 1 beta confers constitutive nuclear factor kappaB activity and chemoresistance in pancreatic carcinoma cell lines. Cancer Res 2002, 62:910-916.
5. Armeanu S., Lauer U.M., Smirnow I., Schenk M., Weiss T.S., Gregor M., Bitzer M. Adenoviral gene transfer of tumor necrosis factor-related apoptosis-inducing ligand overcomes an impaired response of hepatoma cells but causes severe apoptosis in primary human hepatocytes. Cancer Res 2003, 63:2369-2372.
6. Ashkenazi A., Pai R.C., Fong S., Leung S., Lawrence D.A., Marsters S.A., Blackie C., Chang L., McMurtrey A.E., Hebert A., DeForge L., Koumenis I.L., Lewis D., Harris L., Bussiere J., Koeppen H., Shahrokh Z., Schwall R.H. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999, 104:155-162.
7. Austin C.D., Lawrence D.A., Peden A.A., Varfolomeev E.E., Totpal K., De Maziere A.M., Klumperman J., Arnott D., Pham V., Scheller R.H., Ashkenazi A. Death-receptor activation halts clathrin-dependent endocytosis. Proc Natl Acad Sci USA 2006, 103:10283-10288.
8. Barnhart B.C., Legembre P., Pietras E., Bubici C., Franzoso G., Peter M.E. CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells. EMBO J 2004, 23:3175-3185.
9. Begue B., Wajant H., Bambou J.C., Dubuquoy L., Siegmund D., Beaulieu J.F., Canioni D., Berrebi D., Brousse N., Desreumaux P., Schmitz J., Lentze M.J., Goulet O., Cerf-Bensussan N., Ruemmele F.M. Implication of TNF-related apoptosis-inducing ligand in inflammatory intestinal epithelial lesions. Gastroenterology 2006, 130:1962-1974.
10. Bentele M., Lavrik I., Ulrich M., Stosser S., Heermann D.W., Kalthoff H., Krammer P.H., Eils R. Mathematical modeling reveals threshold mechanism in CD95-induced apoptosis. J Cell Biol 2004, 166:839-851.
11. Brockschmidt C., Hirner H., Huber N., Eismann T., Hillenbrand A., Giamas G., Radunsky B., Ammerpohl O., Bohm B., Henne-Bruns D., Kalthoff H., Leithäuser F., Trauzold A., Knippschild U. Anti-apoptotic and growth-stimulatory functions of CK1 delta and epsilon in ductal adenocarcinoma of the pancreas are inhibited by IC261 in vitro and in vivo. Gut 2008, 57:799-806.
12. Chen L., Park S.M., Tumanov A.V., Hau A., Sawada K., Feig C., Turner J.R., Fu Y.X., Romero I.L., Lengyel E., Peter M.E. CD95 promotes tumour growth. Nature 2010, 465:492-496.
13. Christgen M., Schniewind B., Jueschke A., Ungefroren H., Kalthoff H. Gemcitabine-mediated apoptosis is associated with increased CD95 surface expression but is not inhibited by DN-FADD in Colo357 pancreatic cancer cells. Cancer Lett 2005, 227:193-200.
14. Daniels M.A., Teixeiro E., Gill J., Hausmann B., Roubaty D., Holmberg K., Werlen G., Hollander G.A., Gascoigne N.R., Palmer E. Thymic selection threshold defined by compartmentalization of Ras/MAPK signalling. Nature 2006, 444:724-729.
15. Desagher S., Osen-Sand A., Montessuit S., Magnenat E., Vilbois F., Hochmann A., Journot L., Antonsson B., Martinou J.C. Phosphorylation of bid by casein kinases I and II regulates its cleavage by caspase 8. Mol Cell 2001, 8:601-611.
16. Desbarats J., Newell M.K. Fas engagement accelerates liver regeneration after partial hepatectomy. Nat Med 2000, 6:920-923.
17. Desbarats J., Birge R.B., Mimouni-Rongy M., Weinstein D.E., Palerme J.S., Newell M.K. Fas engagement induces neurite growth through ERK activation and p35 upregulation. Nat Cell Biol 2003, 5:118-125.
18. Duiker E.W., Mom C.H., de Jong S., Willemse P.H., Gietema J.A., van der Zee A.G., de Vries E.G. The clinical trail of TRAIL. Eur J Cancer 2006, 42:2233-2240.
19. Egberts J.H., Cloosters V., Noack A., Schniewind B., Thon L., Klose S., Kettler B., von Forstner C., Kneitz C., Tepel J., Adam D., Wajant H., Kalthoff H., Trauzold A. Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res 2008, 68:1443-1450.
20. Egberts J.H., Schniewind B., Patzold M., Kettler B., Tepel J., Kalthoff H., Trauzold A. Dexamethasone reduces tumor recurrence and metastasis after pancreatic tumor resection in SCID mice. Cancer Biol Ther 2008, 7:1044-1050.
21. Ehrenschwender M., Siegmund D., Wicovsky A., Kracht M., Dittrich-Breiholz O., Spindler V., Waschke J., Kalthoff H., Trauzold A., Wajant H. Mutant PIK3CA licenses TRAIL and CD95L to induce non-apoptotic caspase-8-mediated ROCK activation. Cell Death Differ 2010, 17:1435-1447.
22. Falschlehner C., Emmerich C.H., Gerlach B., Walczak H. TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol 2007, 39:1462-1475.
23. Falschlehner C., Ganten T.M., Koschny R., Schaefer U., Walczak H. TRAIL and other TRAIL receptor agonists as novel cancer therapeutics. Adv Exp Med Biol 2009, 647:195-206.
24. Farrow B., Albo D., Berger D.H. The role of the tumor microenvironment in the progression of pancreatic cancer. J Surg Res 2008, 149:319-328.
25. Hamacher R., Schmid R.M., Saur D., Schneider G. Apoptotic pathways in pancreatic ductal adenocarcinoma. Mol Cancer 2008, 7:64.
26. Hinz S., Trauzold A., Boenicke L., Sandberg C., Beckmann S., Bayer E., Walczak H., Kalthoff H., Ungefroren H. Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis. Oncogene 2000, 19:5477-5486.
27. Hoogwater F.J., Nijkamp M.W., Smakman N., Steller E.J., Emmink B.L., Westendorp B.F., Raats D.A., Sprick M.R., Schaefer U., Van Houdt W.J., De Bruijn M.T., Schackmann R.C., Derksen P.W., Medema J.P., Walczak H., Borel Rinkes I.H., Kranenburg O. Oncogenic K-Ras turns death receptors into metastasis-promoting receptors in human and mouse colorectal cancer cells. Gastroenterology 2010, 138:2357-2367.
28. Ibrahim S.M., Ringel J., Schmidt C., Ringel B., Müller P., Koczan D., Thiesen H.J., Löhr M. Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death. Pancreas 2001, 23:72-79.
29. Ischenko I., Seeliger H., Kleespies A., Angele M.K., Eichhorn M.E., Jauch K.W., Bruns C.J. Pancreatic cancer stem cells: new understanding of tumorigenesis, clinical implications. Langenbecks Arch Surg 2010, 395:1-10.
30. Ishimura N., Isomoto H., Bronk S.F., Gores G.J. Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. Am J Physiol Gastrointest Liver Physiol 2006, 290:G129-136.
31. Itoh N., Yonehara S., Ishii A., Yonehara M., Mizushima S., Sameshima M., Hase A., Seto Y., Nagata S. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991, 66:233-243.
32. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
33. Johnstone R.W., Frew A.J., Smyth M.J. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 2008, 8:782-798.
34. Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Kamiyama H., Jimeno A., Hong S.M., Fu B., Lin M.T., Calhoun E.S., Kamiyama M., Walter K., Nikolskaya T., Nikolsky Y., Hartigan J., Smith D.R., Hidalgo M., Leach S.D., Klein A.P., Jaffee E.M., Goggins M., Maitra A., Iacobuzio-Donahue C., Eshleman J.R., Kern S.E., Hruban R.H., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V.E., Kinzler K.W. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321:1801-1806.
35. Death receptors and cognate ligands in cancer. Series: Results Probl Cell Differ 2009, vol. 49. Springer-Verlag, Berlin/Heidelberg. H. Kalthoff (Ed.).
36. Kalthoff H., Trauzold A. Following the death TRAIL to hunt down tumor cells: translating programmed cell death signaling mechanisms into clinical practice. Results Probl Cell Differ 2009, 49:vii-xiii.
37. Kischkel F.C., Hellbardt S., Behrmann I., Germer M., Pawlita M., Krammer P.H., Peter M.E. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J 1995, 14:5579-5588.
38. Knippschild U., Gocht A., Wolff S., Huber N., Löhler J., Stöter M. The casein kinase 1 family: participation in multiple cellular processes in eukaryotes. Cell Signal 2005, 17:675-689.
39. Koorstra J.B., Feldmann G., Habbe N., Maitra A. Morphogenesis of pancreatic cancer: role of pancreatic intraepithelial neoplasia (PanINs). Langenbecks Arch Surg 2008, 393:561-570.
40. Lawrence D., Shahrokh Z., Marsters S., Achilles K., Shih D., Mounho B., Hillan K., Totpal K., DeForge L., Schow P., Hooley J., Sherwood S., Pai R., Leung S., Khan L., Gliniak B., Bussiere J., Smith C.A., Strom S.S., Kelley S., Fox J.A., Thomas D., Ashkenazi A. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001, 7:383-385.
41. Lee K.H., Feig C., Tchikov V., Schickel R., Hallas C., Schutze S., Peter M.E., Chan A.C. The role of receptor internalization in CD95 signaling. EMBO J 2006, 25:1009-1023.
42. Lemke J., Noack A., Adam D., Tchikov V., Bertsch U., Röder C., Schütze S., Wajant H., Kalthoff H., Trauzold A. TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5. J Mol Med 2010, 88:729-740.
43. Letellier E., Kumar S., Sancho-Martinez I., Krauth S., Funke-Kaiser A., Laudenklos S., Konecki K., Klussmann S., Corsini N.S., Kleber S., Drost N., Neumann A., Levi-Strauss M., Brors B., Gretz N., Edler L., Fischer C., Hill O., Thiemann M., Biglari B., Karray S., Martin-Villalba A. CD95-ligand on peripheral myeloid cells activates Syk kinase to trigger their recruitment to the inflammatory site. Immunity 2010, 32:240-252.
44. Li J.H., Kirkiles-Smith N.C., McNiff J.M., Pober J.S. TRAIL induces apoptosis and inflammatory gene expression in human endothelial cells. J Immunol 2003, 171:1526-1533.
45. Loos M., Kleeff J., Friess H., Büchler M.W. Surgical treatment of pancreatic cancer. Ann NY Acad Sci 2008, 1138:169-180.
46. Merino D., Lalaoui N., Morizot A., Schneider P., Solary E., Micheau O. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol 2006, 26:7046-7055.
47. Mihaljevic A.L., Michalski C.W., Friess H., Kleeff J. Molecular mechanism of pancreatic cancer - understanding proliferation, invasion, and metastasis. Langenbecks Arch Surg 2010, 395:295-308.
48. Morel J., Audo R., Hahne M., Combe B. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt. J Biol Chem 2005, 280:15709-15718.
49. Müerköster S., Arlt A., Witt M., Gehrz A., Haye S., March C., Grohmann F., Wegehenkel K., Kalthoff H., Fölsch U.R., Schäfer H. Usage of the NF-kappaB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer. Int J Cancer 2003, 104:469-476.
50. Müerköster S., Wegehenkel K., Arlt A., Witt M., Sipos B., Kruse M.L., Sebens T., Klöppel G., Kalthoff H., Fölsch U.R., Schäfer H. Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1beta. Cancer Res 2004, 64:1331-1337.
51. Palmer E., Naeher D. Affinity threshold for thymic selection through a T-cell receptor-co-receptor zipper. Nat Rev Immunol 2009, 9:207-213.
52. Park S.M., Schickel R., Peter M.E. Nonapoptotic functions of FADD-binding death receptors and their signaling molecules. Curr Opin Cell Biol 2005, 17:610-616.
53. Pennarun B., Meijer A., de Vries E.G., Kleibeuker J.H., Kruyt F., de Jong S. Playing the DISC: turning on TRAIL death receptor-mediated apoptosis in cancer. Biochim Biophys Acta 2010, 1805:123-140.
54. Pukac L., Kanakaraj P., Humphreys R., Alderson R., Bloom M., Sung C., Riccobene T., Johnson R., Fiscella M., Mahoney A., Carrell J., Boyd E., Yao X.T., Zhang L., Zhong L., von Kerczek A., Shepard L., Vaughan T., Edwards B., Dobson C., Salcedo T., Albert V. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 2005, 92:1430-1441.
55. Rowinsky E.K. Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. J Clin Oncol 2005, 23:9394-9407.
56. Rückert F., Dawelbait G., Winter C., Hartmann A., Denz A., Ammerpohl O., Schroeder M., Schackert H.K., Sipos B., Klöppel G., Kalthoff H., Saeger H.D., Pilarsky C., Grützmann R. Examination of apoptosis signaling in pancreatic cancer by computational signal transduction analysis. PLoS One 2010, 5:e12243.
57. Sancho-Martinez I., Martin-Villalba A. Tyrosine phosphorylation and CD95: a FAScinating switch. Cell Cycle 2009, 8:838-842.
58. Scaffidi C., Fulda S., Srinivasan A., Friesen C., Li F., Tomaselli K.J., Debatin K.M., Krammer P.H., Peter M.E. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998, 17:1675-1687.
59. Schneider-Brachert W., Tchikov V., Neumeyer J., Jakob M., Winoto-Morbach S., Held-Feindt J., Heinrich M., Merkel O., Ehrenschwender M., Adam D., Mentlein R., Kabelitz D., Schütze S. Compartmentalization of TNF receptor 1 signaling: internalized TNF receptosomes as death signaling vesicles. Immunity 2004, 21:415-428.
60. Schniewind B., Heintz K., Kurdow R., Ammerpohl O., Trauzold A., Emme D., Dohrmann P., Kalthoff H. Combination phenylbutyrate/gemcitabine therapy effectively inhibits in vitro and in vivo growth of NSCLC by intrinsic apoptotic pathways. J Carcinog 2006, 5:25.
61. Secchiero P., Gonelli A., Carnevale E., Corallini F., Rizzardi C., Zacchigna S., Melato M., Zauli G. Evidence for a proangiogenic activity of TNF-related apoptosis-inducing ligand. Neoplasia 2004, 6:364-373.
62. Siegmund D., Klose S., Zhou D., Baumann B., Röder C., Kalthoff H., Wajant H., Trauzold A. Role of caspases in CD95L- and TRAIL-induced non-apoptotic signalling in pancreatic tumour cells. Cell Signal 2007, 19:1172-1184.
63. Takeda K., Stagg J., Yagita H., Okumura K., Smyth M.J. Targeting death-inducing receptors in cancer therapy. Oncogene 2007, 26:3745-3757.
64. Tepel J., Kruse M.L., Kapischke M., Haye S., Sipos B., Kremer B., Kalthoff H. Adjuvant treatment of pancreatic carcinoma in a clinically adapted mouse resection model. Pancreatology 2006, 6:240-247.
65. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
66. Trauzold A., Wermann H., Arlt A., Schütze S., Schäfer H., Oestern S., Röder C., Ungefroren H., Lampe E., Heinrich M., Walczak H., Kalthoff H. CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-kappaB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells. Oncogene 2001, 20:4258-4269.
67. Trauzold A., Schmiedel S., Röder C., Tams C., Christgen M., Oestern S., Arlt A., Westphal S., Kapischke M., Ungefroren H., Kalthoff H. Multiple and synergistic deregulations of apoptosis-controlling genes in pancreatic carcinoma cells. Br J Cancer 2003, 89:1714-1721.
68. Trauzold A., Schmiedel S., Sipos B., Wermann H., Westphal S., Röder C., Klapper W., Arlt A., Lehnert L., Ungefroren H., Johannes F.J., Kalthoff H. PKCmu prevents CD95-mediated apoptosis and enhances proliferation in pancreatic tumour cells. Oncogene 2003, 22:8939-8947.
69. Trauzold A., Röder C., Sipos B., Karsten K., Arlt A., Jiang P., Martin-Subero J.I., Siegmund D., Müerköster S., Pagerols-Raluy L., Siebert R., Wajant H., Kalthoff H. CD95 and TRAF2 promote invasiveness of pancreatic cancer cells. FASEB J 2005, 19:620-622.
70. Trauzold A., Siegmund D., Schniewind B., Sipos B., Egberts J., Zorenkov D., Emme D., Röder C., Kalthoff H., Wajant H. TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene 2006, 25:7434-7439.
71. Ungefroren H., Voss M., Jansen M., Roeder C., Henne-Bruns D., Kremer B., Kalthoff H. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. Cancer Res 1998, 58:1741-1749.
72. Ungefroren H., Kruse M.L., Trauzold A., Roeschmann S., Roeder C., Arlt A., Henne-Bruns D., Kalthoff H. FAP-1 in pancreatic cancer cells: functional and mechanistic studies on its inhibitory role in CD95-mediated apoptosis. J Cell Sci 2001, 114:2735-2746.
73. Van Herreweghe F., Festjens N., Declercq W., Vandenabeele P. Tumor necrosis factor-mediated cell death: to break or to burst, that's the question. Cell Mol Life Sci 2010, 67:1567-1579.
74. Varfolomeev E., Maecker H., Sharp D., Lawrence D., Renz M., Vucic D., Ashkenazi A. Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J Biol Chem 2005, 280:40599-40608.
75. Wajant H., Pfizenmaier K., Scheurich P. Non-apoptotic Fas signaling. Cytokine Growth Factor Rev 2003, 14:53-66.
76. Walczak H., Miller R.E., Ariail K., Gliniak B., Griffith T.S., Kubin M., Chin W., Jones J., Woodward A., Le T., Smith C., Smolak P., Goodwin R.G., Rauch C.T., Schuh J.C., Lynch D.H. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999, 5:157-163.
77. Yanagisawa J., Takahashi M., Kanki H., Yano-Yanagisawa H., Tazunoki T., Sawa E., Nishitoba T., Kamishohara M., Kobayashi E., Kataoka S., Sato T. The molecular interaction of Fas and FAP-1. A tripeptide blocker of human Fas interaction with FAP-1 promotes Fas-induced apoptosis. J Biol Chem 1997, 272:8539-8545.